吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jan 13 2021

Full Issue

Perspectives: Cutting Down On Bad Patents Can Help Drug Prices

Read recent commentaries about drug-cost issues.

Though President Trump spent the past four years railing against drug manufacturers, his administration had little success in curbing pharmaceutical prices. In 2019 alone, Americans spent an astonishing $82 billion out-of-pocket on prescription drugs. That鈥檚 an 11-percent increase since 2015. This has real human costs: A recent Washington Post investigation found Americans risking their lives because they cannot afford modern insulin treatments. A divided Senate may struggle to address rising drug prices, but the Biden White House can fix one of the most broken aspects of our drug system with no help from Congress. It can give out fewer bad patents. (Doni Bloomfield and Aaron S. Kesselheim, 1/5)

Also 鈥

In a series of changes, some of them a half-century overdue, Mr. Trump also helped remove government obstacles to innovation and competition in health care. Democrats will tell you that the first calendar-year drop in retail prescription drug prices in 46 years was mere coincidence, not the result of deregulation. Mr. Trump鈥檚 first redirection of the Food and Drug Administration proved to be a warm-up act for Operation Warp Speed, which shocked the 鈥渆xperts鈥 who predicted there was no way a Covid-19 vaccine could be approved in 2020. (Casey B. Mulligan, 1/5)

His days in the White House may be numbered, but that didn't deter President Donald聽Trump from handing down his most sweeping health care reform to date. The president recently announced the final rule for his "Most Favored Nation" executive order, which requires Medicare to pay drug makers no more for certain medications than nations with wealth comparable to ours pay. (Kenneth E. Thorpe, 1/6)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF